Pfizer reaffirms 2026 guidance after CFO transition news
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $24.82 -0.48%
Revenue Growth %: -1.9%
Financial Fact:
Restructuring charges and certain acquisition-related costs: 531M
Today's EPS Names:
HYFT, ESBS, PFBK, More
Revenue Growth %: -1.9%
Financial Fact:
Restructuring charges and certain acquisition-related costs: 531M
Today's EPS Names:
HYFT, ESBS, PFBK, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) reaffirmed its full-year 2026 financial guidance following the announcement of a Chief Financial Officer transition on June 18, 2026.
The company maintained its forecast for revenues in a range of $59.5 billion to $62.5 billion, and adjusted diluted earnings per share in a range of $2.80 to $3.00. The guidance was originally introduced on December 16, 2025, and was previously reaffirmed during Pfizer's first-quarter earnings call on May 5, 2026.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
- Shutterstock's chief accounting officer to resign in August
- Goosehead Insurance Inc. (GSHD) Tops Q2 EPS by 16c
Create E-mail Alert Related Categories
Corporate News, Guidance, Management ChangesRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
